Skip to content
Compare stocks

City Therapeutics vs SpyGlass Pharma vs Vor Biopharma

Score, categories, valuation, dividend, crash risk and price performance of City Therapeutics, SpyGlass Pharma and Vor Biopharma side by side. Figures from the overnight run, closing prices from 19 Nov 2026.

Key figures compared

CTYCity TherapeuticsSGPSpyGlass PharmaVORVor Biopharma
MEQIRI Score
Score584545
Fundamentals911020
Growth335050
Profitability821214
Valuationno datano datano data
Technical analysis396261
Momentum199382
Stability627249
Capital allocation644162
Price and valuation
Closing price$18.35$30.78$18.52
Market cap$979.67M$1.03B$1B
P/Eno dataLossLoss
Forward P/Eno dataLoss expectedno data
Fair valueno datano datano data
Fair value versus priceno datano datano data
Growth and dividend
Revenue growth per year−1.6%no datano data
Dividend yield0.0%0.0%0.0%
Risk and performance
Crash riskno datano datano data
Price 1 yearno datano data+136.8%
Price 5 yearsno datano data−93.2%
IndustryBiotechnologyBiotechnologyBiotechnology

Score and figures from the overnight run, closing prices from 19 Nov 2026. Amounts in US dollars, converted at the ECB rate. Price performance without dividends. The comparison shows figures and is not a recommendation to buy.

Price performance

  • City Therapeutics
  • SpyGlass Pharma
  • Vor Biopharma

All lines start at 100 on 15 October 2026, the first trading day of the youngest stock. Closing prices without dividends, each stock in its trading currency.

Questions and Answers

How do City Therapeutics, SpyGlass Pharma and Vor Biopharma compare on the MEQIRI Score?

The MEQIRI Score (0 to 100) is 58 for City Therapeutics, 45 for SpyGlass Pharma and 45 for Vor Biopharma. The category Fundamentals differs most, with 91 for City Therapeutics, 10 for SpyGlass Pharma and 20 for Vor Biopharma. The score combines eight categories and is recalculated every night.

What is the P/E ratio of City Therapeutics, SpyGlass Pharma and Vor Biopharma?

City Therapeutics: P/E no data, forward P/E no data. SpyGlass Pharma: P/E Loss, forward P/E Loss expected. Vor Biopharma: P/E Loss, forward P/E no data. As of the close on 19 Nov 2026.

What is the dividend yield of City Therapeutics, SpyGlass Pharma and Vor Biopharma?

City Therapeutics: 0.0%. SpyGlass Pharma: 0.0%. Vor Biopharma: 0.0%. Based on payments over the last twelve months.

What is the crash risk of City Therapeutics, SpyGlass Pharma and Vor Biopharma?

City Therapeutics: no data. SpyGlass Pharma: no data. Vor Biopharma: no data. Crash risk means a fall of 30% or more within a year, measured in the backtest against companies of similar size.

Why does the price chart start at 100?

All lines start at 100 on the same day. That shows performance regardless of a stock's price: 150 means 50% more than at the start, 80 means 20% less.

Does the comparison tell me which stock to buy?

No. MEQIRI shows figures and explains them, but gives no buy recommendation and no price target. The score helps you see strengths and weaknesses faster.

More comparisons

Compare stocks